Chasing a 100 times return might not be a great idea. But there are lessons to be taken from past winners of this magnitude.

Here are two beaten-down stocks that long-term investors might want to consider buying on the dip and holding for several ...

Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Pfizer's generous dividend has become a big ...

Robert F. Kennedy Jr., the health secretary and a longtime vaccine critic, announced in a statement Tuesday that $500 million ...

These five large-cap value dividend stocks look poised to provide some second-half gains with steady ultra-high-yield ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...